Patents by Inventor John B. Vincent

John B. Vincent has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Biomarkers for Autism Spectrum Disorders
    Publication number: 20220136055
    Abstract: Methods of determining the risk of ASD in an individual are provided which comprise identifying the presence of one or more genomic mutations in one or more of the genes, PTCHD1, SHANK3, NFIA, DPP6, DPP10, DYPD, GPR98, PQBP1, ZNF41 and FTSJ1.
    Type: Application
    Filed: January 21, 2022
    Publication date: May 5, 2022
    Inventors: Stephen W Scherer, John B Vincent
  • Biomarkers for autism spectrum disorders
    Patent number: 11254984
    Abstract: Methods of determining the risk of ASD in an individual are provided which comprise identifying the presence of one or more genomic mutations in one or more of the genes, PTCHD1, SHANK3, NFIA, DPP6, DPP10, DYPD, GPR98, PQBP1, ZNF41 and FTSJ1.
    Type: Grant
    Filed: November 25, 2019
    Date of Patent: February 22, 2022
    Assignee: The Hospital for Sick Children
    Inventors: Stephen W Scherer, John B Vincent
  • MECP2E1 GENE
    Publication number: 20200270693
    Abstract: The invention is a novel MECP2E1 splice variant and its corresponding polypeptide. The invention also includes methods of using these nucleic acid sequences and proteins in medical diagnosis and treatment of neuropsychiatric disorders or development disorders.
    Type: Application
    Filed: March 2, 2020
    Publication date: August 27, 2020
    Applicants: The Hospital for Sick Children, Centre for Addiction and Mental Health
    Inventors: Berge A. Minassian, John B. Vincent
  • MECP2E1 GENE
    Publication number: 20200270695
    Abstract: The invention is a novel MECP2E1 splice variant and its corresponding polypeptide. The invention also includes methods of using these nucleic acid sequences and proteins in medical diagnosis and treatment of neuropsychiatric disorders or development disorders.
    Type: Application
    Filed: March 2, 2020
    Publication date: August 27, 2020
    Applicants: The Hospital For Sick Children, Centre for Addiction and Mental Health
    Inventors: Berge A. Minassian, John B. Vincent
  • Biomarkers for Autism Spectrum Disorders
    Publication number: 20200157628
    Abstract: Methods of determining the risk of ASD in an individual are provided which comprise identifying the presence of one or more genomic mutations in one or more of the genes, PTCHD1, SHANK3, NFIA, DPP6, DPP10, DYPD, GPR98, PQBP1, ZNF41 and FTSJ1.
    Type: Application
    Filed: November 25, 2019
    Publication date: May 21, 2020
    Inventors: Stephen W Scherer, John B Vincent
  • MECP2E1 gene
    Patent number: 10577658
    Abstract: The invention is a novel MECP2E1 splice variant and its corresponding polypeptide. The invention also includes methods of using these nucleic acid sequences and proteins in medical diagnosis and treatment of neuropsychiatric disorders or development disorders.
    Type: Grant
    Filed: March 7, 2018
    Date of Patent: March 3, 2020
    Assignees: The Hospital for Sick Children, Centre for Addiction and Mental Health
    Inventors: Berge A. Minassian, John B. Vincent
  • MECP2E1 gene
    Patent number: 10577657
    Abstract: The invention is a novel MECP2E1 splice variant and its corresponding polypeptide. The invention also includes methods of using these nucleic acid sequences and proteins in medical diagnosis and treatment of neuropsychiatric disorders or development disorders.
    Type: Grant
    Filed: March 7, 2018
    Date of Patent: March 3, 2020
    Assignees: The Hospital For Sick Children, Centre for Addiction and Mental Health
    Inventors: Berge A. Minassian, John B. Vincent
  • Biomarkers for autism spectrum disorders
    Patent number: 10526653
    Abstract: Methods of determining the risk of ASD in an individual are provided which comprise identifying the presence of one or more genomic mutations in one or more of the genes, PTCHD1, SHANK3, NFIA, DPP6, DPP10, DYPD, GPR98, PQBP1, ZNF41 and FTSJ1.
    Type: Grant
    Filed: February 24, 2015
    Date of Patent: January 7, 2020
    Assignees: The Centre for Addiction and Mental Health, The Hospital for Sick Children
    Inventors: Stephen W Scherer, John B Vincent
  • MECP2E1 GENE
    Publication number: 20180265927
    Abstract: The invention is a novel MECP2E1 splice variant and its corresponding polypeptide. The invention also includes methods of using these nucleic acid sequences and proteins in medical diagnosis and treatment of neuropsychiatric disorders or development disorders.
    Type: Application
    Filed: March 7, 2018
    Publication date: September 20, 2018
    Applicants: The Hospital for Sick Children, Centre for Addiction and Mental Health
    Inventors: Berge A. Minassian, John B. Vincent
  • MECP2E1 GENE
    Publication number: 20180265926
    Abstract: The invention is a novel MECP2E1 splice variant and its corresponding polypeptide. The invention also includes methods of using these nucleic acid sequences and proteins in medical diagnosis and treatment of neuropsychiatric disorders or development disorders.
    Type: Application
    Filed: March 7, 2018
    Publication date: September 20, 2018
    Applicants: The Hospital For Sick Children, Centre for Addiction and Mental Health
    Inventors: Berge A. Minassian, John B. Vincent
  • CC2D2A gene mutations associated with Joubert syndrome and diagnostic methods for identifying the same
    Patent number: 9670544
    Abstract: The present invention provides a method of screening a subject for mutations in the CC2D2A gene that are associated with Joubert syndrome, an autosomal recessive form of mental retardation. The present invention also provides proteins that are associated with Joubert syndrome including proteins that includes an amino acid sequence that terminates in DHEGGSGMES (SEQ ID NO: 1). Also provided are nucleotide sequences encoding such proteins and methods of screening subjects to identify nucleotide sequences or proteins associated with Joubert syndrome.
    Type: Grant
    Filed: June 29, 2015
    Date of Patent: June 6, 2017
    Assignee: Centre for Addiction and Mental Health
    Inventors: John B. Vincent, Muhammad Ayub
  • MECP2E1 GENE
    Publication number: 20170152564
    Abstract: The invention is a novel MECP2E1 splice variant and its corresponding polypeptide. The invention also includes methods of using these nucleic acid sequences and proteins in medical diagnosis and treatment of neuropsychiatric disorders or development disorders.
    Type: Application
    Filed: February 9, 2017
    Publication date: June 1, 2017
    Applicants: The Hospital for Sick Children, Centre for Addiction and Metal Health
    Inventors: Berge A. Minassian, John B. Vincent
  • MECP2E1 GENE
    Publication number: 20170137887
    Abstract: The invention is a novel MECP2E1 splice variant and its corresponding polypeptide. The invention also includes methods of using these nucleic acid sequences and proteins in medical diagnosis and treatment of neuropsychiatric disorders or development disorders.
    Type: Application
    Filed: January 31, 2017
    Publication date: May 18, 2017
    Applicants: The Hospital for Sick Children, Centre for Addiction and Mental Health
    Inventors: Berge A. Minassian, John B. Vincent
  • MECP2E1 gene
    Patent number: 9605314
    Abstract: The invention is a novel MECP2E1 splice variant and its corresponding polypeptide. The invention also includes methods of using these nucleic acid sequences and proteins in medical diagnosis and treatment of neuropsychiatric disorders or development disorders.
    Type: Grant
    Filed: December 9, 2013
    Date of Patent: March 28, 2017
    Assignees: The Hospital for Sick Children, Centre for Addiction and Mental Health
    Inventors: Berge A. Minassian, John B. Vincent
  • MECP2E1 gene
    Patent number: 9568484
    Abstract: The invention is a novel MECP2E1 splice variant and its corresponding polypeptide. The invention also includes methods of using these nucleic acid sequences and proteins in medical diagnosis and treatment of neuropsychiatric disorders or development disorders.
    Type: Grant
    Filed: November 18, 2008
    Date of Patent: February 14, 2017
    Assignees: Centre for Addiction and Mental Health, The Hospital for Sick Children
    Inventors: Berge A. Minassian, John B. Vincent
  • BIOMARKERS FOR AUTISM SPECTRUM DISORDERS
    Publication number: 20150322518
    Abstract: Methods of determining the risk of ASD in an individual are provided which comprise identifying the presence of one or more genomic mutations in one or more of the genes, PTCHD1, SHANK3, NFIA, DPP6, DPP10, DYPD, GPR98, PQBP1, ZNF41 and FTSJ1.
    Type: Application
    Filed: February 24, 2015
    Publication date: November 12, 2015
    Inventors: Stephen W. Scherer, John B. Vincent
  • IDENTIFICATION OF THE DCPS GENE ON 11Q24.2, WHICH ENCODES THE HUMAN DECAPPING ENZYME SCAVENGER, IN NON-SYNDROMIC AUTOSOMAL RECESSIVE MENTAL RETARDATION, DIAGNOSTIC PROBES THEREOF AND METHODS OF IDENTIFYING SUBJECTS WITH SAME
    Publication number: 20150315640
    Abstract: Provided herein is a DCPS nucleotide sequence on 11q24.2, which encodes the human decapping enzyme scavenger, associated with non-syndromic autosomal recessive mental retardation, diagnostic probes thereof, mutant proteins encoded thereby and methods of identifying subjects with same.
    Type: Application
    Filed: November 7, 2013
    Publication date: November 5, 2015
    Applicant: Centre for Addiction and Mental Health
    Inventor: John B. Vincent
  • CC2D2A GENE MUTATIONS ASSOCIATED WITH JOUBERT SYNDROME AND DIAGNOSTIC METHODS FOR IDENTIFYING THE SAME
    Publication number: 20150315650
    Abstract: The present invention provides a method of screening a subject for mutations in the CC2D2A gene that are associated with Joubert syndrome, an autosomal recessive form of mental retardation. The present invention also provides proteins that are associated with Joubert syndrome including proteins that includes an amino acid sequence that terminates in DHEGGSGMES (SEQ ID NO: 1). Also provided are nucleotide sequences encoding such proteins and methods of screening subjects to identify nucleotide sequences or proteins associated with Joubert syndrome.
    Type: Application
    Filed: June 29, 2015
    Publication date: November 5, 2015
    Inventors: John B. VINCENT, Muhammad AYUB
  • CC2D2A gene mutations associated with Joubert syndrome and diagnostic methods for identifying the same
    Patent number: 9096903
    Abstract: The present invention provides a method of screening a subject for mutations in the CC2D2A gene that are associated with Joubert syndrome, an autosomal recessive form of mental retardation. The present invention also provides proteins that are associated with Joubert syndrome including proteins that includes an amino acid sequence that terminates in DHEGGSGMES (SEQ ID NO: 1). Also provided are nucleotide sequences encoding such proteins and methods of screening subjects to identify nucleotide sequences or proteins associated with Joubert syndrome.
    Type: Grant
    Filed: December 2, 2013
    Date of Patent: August 4, 2015
    Assignee: Centre for Addiction and Mental Health
    Inventors: John B. Vincent, Muhammad Ayub
  • GENETIC MARKERS ASSOCIATED WITH INTELLECTUAL DISABILITY
    Publication number: 20150141287
    Abstract: Genetic markers associated with intellectual disability as well as compositions, methods and kits for screening for genetic markers of intellectual disability, diagnosing intellectual disability and identifying individuals with a predisposition for offspring suffering from intellectual disability are provided.
    Type: Application
    Filed: January 22, 2015
    Publication date: May 21, 2015
    Inventor: John B. Vincent